Patients with late-stage lung and skin cancer may have just won an unlikely ally: the COVID-19 mRNA vaccine. Researchers at ...

Over the last year, Noubar Afeyan has watched Cambridge-based Moderna go from perhaps the world’s most celebrated company ...

To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize ...

The mRNA technology that helped combat the global COVID-19 pandemic may now offer new hope in the fight against cancer, ...

By casting doubt about the promise of mRNA tech, RFK Jr. is slowing progress toward highly effective therapies that could ...

Multilateral initiatives are needed to signal confidence and fill funding gaps in mRNA research, writes Jennifer B Nuzzo ...

Researchers found that among cancer patients getting immunotherapy, those who got an mRNA Covid vaccine within 100 days ...

A team of researchers from Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Tsinghua ...

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m ...

RNA COVID-19 vaccines — originally developed to protect against the coronavirus — may be providing an additional, unexpected health advantage.

Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy ...